On February 26, 2024 Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, reported that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth’s sponsored scientific research conducted at NC State University (Press release, Hoth Therapeutics, FEB 26, 2024, View Source [SID1234640474]). The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to make strides in moving HT-KIT from the lab to patients and this further analysis will help us with that process as a final step in the preclinical development that allows us to finalizing the protocols in our upcoming IND-enabling," stated Robb Knie, Chief Executive Officer. "We are pleased to further engage Altasciences on these studies given its great reputation for full-service solutions including preclinical safety testing, clinical pharmacology and bioanalysis."

On February 26, 2024 GC Cell, a fully integrated cell therapy pioneer reported a strategic partnership with BioCentriq, a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell (Press release, GC Cell, FEB 26, 2024, View Source [SID1234640473]). This important partnership lays the foundation to bring GC Cells’ proven cell-based immunotherapy, Immuncell-LC to the North American market. The execution of a Process Transfer Agreement with BioCentriq effectively lays the foundation for the U.S. launch of Immuncell-LC through utilization of BioCentriq’s cell therapy process development, analytical method development and manufacturing expertise.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Process Transfer Agreement between GC Cell and BioCentriq initiates the groundwork for introducing Immuncell-LC to the U.S. market" said James Park, CEO of GC Cell. Our partnership with BioCentriq underscores our commitment to bringing innovative cancer therapies to patients in need across North America, marking a significant milestone in GC Cell’s global expansion strategy."

"We are thrilled to partner with GC Cell to bring Immuncell-LC, a proven autologous cell therapy to the U.S. Market. Our partnership further enables our mission of Delivering Hope to cancer patients with significant unmet medical needs" said Jennifer Manning, Chief Commercial Officer, BioCentriq.

Immuncell-LC is the only commercially available adoptive cell therapy treatment of early-stage HCC. It is primarily composed of autologous, cultured blood-derived T lymphocytes with proven efficacy through a large-scale Phase 3 clinical trial which reduced the risk of recurrence by 37% and decreased the mortality rate by 79% compared to the control group. To date, Immuncell-LC has been administered to over 10,000 patients in South Korea without serious adverse events.

On February 26, 2024 J INTS BIO reported that the Phase 1/2 clinical study of its Novel Oral 4th Generation EGFR TKI "JIN-A02" for the treatment of NSCLC has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) meeting to be held in San Diego USA from 5 to 10 April (Press release, J INTS BIO, FEB 26, 2024, View Source [SID1234640472]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The American Association for Cancer Research (AACR) (Free AACR Whitepaper) is an authoritative cancer society and is considered one of the world’s top three societies in the field of cancer, along with the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper). J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".

‘JIN-A02’, a 4th generation EGFR-TKI, selectively binds to C797S, a mutation that leads to resistance to the use of 3rd generation EGFR-TKIs (such as Osimertinib, Lazertinib), in the treatment of EGFR+ NSCLC. ‘JIN-A02’ is highly selective for and strongly inhibits NSCLC with C797S double or triple mutations and is expected to show efficacy against intracranial tumors due to its high blood-brain barrier permeability.

In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of ‘JIN-A02’ at Severance Hospital in Korea. This clinical study is currently recruiting patients with EGFR mutation-positive and advanced NSCLC at in Korea, including Asan Medical Center and the National Cancer Center, and the University of California (U.C. Irvine).

The dose escalation part of the study is now at its 4th dose level, and despite the preceding low dose levels, early efficacy responses were observed in targeted lesions, especially in patients with the C797S mutation. J INTS BIO plans to expand the number of clinical trial sites globally and in Korea, this will include Seoul National University Hospital, Samsung Seoul Hospital, and Seoul St. Mary’s Hospital.

A J INTS BIO official said, "The global clinical trial for ‘JIN-A02’ is progressing well and is receiving interest in the global market."

Details of the AACR (Free AACR Whitepaper) presentation will be released on April 8th.

On February 26, 2024 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, on Monday, March 11, 2024 at 11:20 AM ET (Press release, Compugen, FEB 26, 2024, View Source [SID1234640471]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investor Relations section of Compugen’s website at www.cgen.com. A replay will be available following the live event.

On February 26, 2024 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported that the Company will participate in two upcoming investor conferences (Press release, Fusion Pharmaceuticals, FEB 26, 2024, View Source [SID1234640470]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 44th Annual Health Care Conference – The Company will participate in the "Prostate Cancer Corporate Panel Discussion" taking place on March 4, 2024, at 10:30 a.m. ET in Boston, MA. Participating on behalf of Fusion will be President and Chief Business Officer Mohit Rawat.

Leerink Partners 2024 Global Biopharma Conference – The Company fireside chat presentation will take place on Tuesday, March 12, 2024, at 4:20 p.m. ET in Miami, FL. Participating on behalf of Fusion will be President and Chief Business Officer Mohit Rawat.

Webcasts of each event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following their respective presentation dates.